Vitamin K2 for Bone Health in Kids with Nephrotic Syndrome
The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome
Recruiting
N/A
Interventional Study
Pediatrics Nephrology
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 1 – 16
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 60 (estimated)
- Sponsor
- Ain Shams University · Other
Who this trial is looking for
This trial is looking for children under 16 with nephrotic syndrome who are taking glucocorticoids. Participants will take vitamin K2 to see how it affects their bone health.
Are You a Good Fit for This Trial?
You may be able to join if
- I am under 16 years old.
- I have nephrotic syndrome.
- I am taking glucocorticoids for the first time.
- I have been on glucocorticoids for more than 6 months.
- My vitamin D level is 30 ng/ml or above.
You may not be able to join if
- I have impaired kidney function.
- I do not follow medication or vitamin guidelines.
- I have a disease that affects how my body absorbs fat-soluble vitamins.
- I have a history of bleeding disorders or bone diseases.
- I have broken a bone before this study.
- My nephrotic syndrome has a genetic cause.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Long-term glucocorticoids therapy is associated with various complications, including decreased bone strength (Glucocorticoid-induced osteoporosis) and an increased risk of fracture.
Vitamin K2 has been recently deemed appreciable as a topic of research as it plays a pivotal role in maintenance of the bone strength, and it has been proved to have a positive impact on the bone metabolism.
This st…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Nephrotic patients under 16 years of age of both genders who were treated with GC for the first time. GC treatment was initiated at a dose of 2 mg/kg/day prednisolone with gradual dose reduction.
* All patients have been on glucocorticoid therapy for more than 6 months. All pa…
Contacts